Clinical Trial: Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
Study Status: Completed
Recruit Status: RECRUITING
Condition: Thyroid Eye Disease
Study Type: INTERVENTIONAL
Official Title: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED)
Brief Summary:
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
Read more